APA (7th ed.) Citation

JA, G., G, S., M, P., B, B., M, R., A, C., . . . D, S. (2025). Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies. International journal of cancer, 157(4), 709. https://doi.org/10.1002/ijc.35432

Chicago Style (17th ed.) Citation

JA, García-Saenz, et al. "Body Mass Index as a Predictive Factor for Efficacy of Adjuvant Taxane-based Chemotherapy in Early-stage Breast Cancer Patients: A Pooled Analysis from Adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group Studies." International Journal of Cancer 157, no. 4 (2025): 709. https://doi.org/10.1002/ijc.35432.

MLA (9th ed.) Citation

JA, García-Saenz, et al. "Body Mass Index as a Predictive Factor for Efficacy of Adjuvant Taxane-based Chemotherapy in Early-stage Breast Cancer Patients: A Pooled Analysis from Adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group Studies." International Journal of Cancer, vol. 157, no. 4, 2025, p. 709, https://doi.org/10.1002/ijc.35432.